Investigation of the Safety and Tolerability of BSCT (Anti-nf-P2X7) 10% Ointment

NCT02587819 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

21

Enrollment

INDUSTRY

Sponsor class

Conditions

Carcinoma, Basal Cell (BCC)

Interventions

DRUG: Treatment with BSCT

Sponsor

Biosceptre

Collaborators

[object Object]